Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.

Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD, Wasik MA.

Mol Cancer Res. 2019 Jun;17(6):1365-1377. doi: 10.1158/1541-7786.MCR-18-0256. Epub 2019 Mar 12.

PMID:
30862686
2.

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.

Sullivan-Reed K, Bolton-Gillespie E, Dasgupta Y, Langer S, Siciliano M, Nieborowska-Skorska M, Hanamshet K, Belyaeva EA, Bernhardy AJ, Lee J, Moore M, Zhao H, Valent P, Matlawska-Wasowska K, Müschen M, Bhatia S, Bhatia R, Johnson N, Wasik MA, Mazin AV, Skorski T.

Cell Rep. 2018 Jun 12;23(11):3127-3136. doi: 10.1016/j.celrep.2018.05.034.

3.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.

Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.

4.

SATB1 in Malignant T Cells.

Fredholm S, Willerslev-Olsen A, Met Ö, Kubat L, Gluud M, Mathiasen SL, Friese C, Blümel E, Petersen DL, Hu T, Nastasi C, Lindahl LM, Buus TB, Krejsgaard T, Wasik MA, Kopp KL, Koralov SB, Persson JL, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Becker JC, Ødum N.

J Invest Dermatol. 2018 Aug;138(8):1805-1815. doi: 10.1016/j.jid.2018.03.1526. Epub 2018 May 8.

PMID:
29751003
5.

Distinct miRNA profile in prognosis of early CTCL.

Wasik MA.

Blood. 2018 Feb 15;131(7):711. doi: 10.1182/blood-2017-12-821520. No abstract available.

6.

Cell culture-based production of defective interfering particles for influenza antiviral therapy.

Wasik MA, Eichwald L, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2018 Feb;102(3):1167-1177. doi: 10.1007/s00253-017-8660-3. Epub 2017 Dec 5.

7.

Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.

Obstfeld AE, Frey NV, Mansfield K, Lacey SF, June CH, Porter DL, Melenhorst JJ, Wasik MA.

Blood. 2017 Dec 7;130(23):2569-2572. doi: 10.1182/blood-2017-08-802413. Epub 2017 Oct 26. No abstract available.

8.

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).

Werner MT, Zhang Q, Wasik MA.

Cancers (Basel). 2017 Oct 16;9(10). pii: E138. doi: 10.3390/cancers9100138. Review.

9.

IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.

Maifrede S, Martin K, Podszywalow-Bartnicka P, Sullivan-Reed K, Langer SK, Nejati R, Dasgupta Y, Hulse M, Gritsyuk D, Nieborowska-Skorska M, Lupey-Green LN, Zhao H, Piwocka K, Wasik MA, Tempera I, Skorski T.

Mol Cancer Res. 2017 Aug;15(8):967-972. doi: 10.1158/1541-7786.MCR-16-0468. Epub 2017 Jun 20.

10.

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.

Ruella M, Klichinsky M, Kenderian SS, Shestova O, Ziober A, Kraft DO, Feldman M, Wasik MA, June CH, Gill S.

Cancer Discov. 2017 Oct;7(10):1154-1167. doi: 10.1158/2159-8290.CD-16-0850. Epub 2017 Jun 2.

11.

Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.

Hatem J, Schrank-Hacker AM, Watt CD, Morrissette JJ, Rubin AI, Kim EJ, Nasta SD, Wasik MA, Bogusz AM.

Diagn Pathol. 2016 Dec 19;11(1):137.

12.

Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.

Werner MT, Zhao C, Zhang Q, Wasik MA.

Blood. 2017 Feb 16;129(7):823-831. doi: 10.1182/blood-2016-05-717793. Epub 2016 Nov 22. Review.

13.

Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover.

Krejsgaard T, Lindahl LM, Mongan NP, Wasik MA, Litvinov IV, Iversen L, Langhoff E, Woetmann A, Odum N.

Semin Immunopathol. 2017 Apr;39(3):269-282. doi: 10.1007/s00281-016-0594-9. Epub 2016 Oct 7. Review.

14.

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S.

Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28. No abstract available.

PMID:
27677739
15.

(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.

Shestov AA, Lee SC, Nath K, Guo L, Nelson DS, Roman JC, Leeper DB, Wasik MA, Blair IA, Glickson JD.

Front Oncol. 2016 Jun 15;6:135. doi: 10.3389/fonc.2016.00135. eCollection 2016.

16.

STAT5 induces miR-21 expression in cutaneous T cell lymphoma.

Lindahl LM, Fredholm S, Joseph C, Nielsen BS, Jønson L, Willerslev-Olsen A, Gluud M, Blümel E, Petersen DL, Sibbesen N, Hu T, Nastasi C, Krejsgaard T, Jæhger D, Persson JL, Mongan N, Wasik MA, Litvinov IV, Sasseville D, Koralov SB, Bonefeld CM, Geisler C, Woetmann A, Ralfkiaer E, Iversen L, Odum N.

Oncotarget. 2016 Jul 19;7(29):45730-45744. doi: 10.18632/oncotarget.10160.

17.

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, Feldman MD, Porter DL, Grupp SA, June CH, Milone MC.

Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May 10.

18.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Müschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T.

Blood. 2016 Apr 28;127(17):2131-43. doi: 10.1182/blood-2015-11-681171. Epub 2016 Feb 10.

19.

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar OU, Milone M, Lacey SF, Mato A, Schuster SJ, Kalos M, June CH, Gill S, Wasik MA.

Clin Cancer Res. 2016 Jun 1;22(11):2684-96. doi: 10.1158/1078-0432.CCR-15-1527. Epub 2016 Jan 27.

20.

Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Litvinov IV, Fredholm S, Petersen DL, Nastasi C, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Bonefeld CM, Geisler C, Woetmann A, Iversen L, Kilian M, Koralov SB, Odum N.

Blood. 2016 Mar 10;127(10):1287-96. doi: 10.1182/blood-2015-08-662353. Epub 2016 Jan 5.

21.

Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.

Sibbesen NA, Kopp KL, Litvinov IV, Jønson L, Willerslev-Olsen A, Fredholm S, Petersen DL, Nastasi C, Krejsgaard T, Lindahl LM, Gniadecki R, Mongan NP, Sasseville D, Wasik MA, Iversen L, Bonefeld CM, Geisler C, Woetmann A, Odum N.

Oncotarget. 2015 Aug 21;6(24):20555-69.

22.

Folding Optimization In Vivo Uncovers New Chaperones.

Lennon CW, Thamsen M, Friman ET, Cacciaglia A, Sachsenhauser V, Sorgenfrei FA, Wasik MA, Bardwell JC.

J Mol Biol. 2015 Sep 11;427(18):2983-94. doi: 10.1016/j.jmb.2015.05.013. Epub 2015 May 21.

23.

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.

Bagdonaite I, Wandall HH, Litvinov IV, Nastasi C, Becker JC, Dabelsteen S, Geisler C, Bonefeld CM, Zhang Q, Wasik MA, Zhou Y, Sasseville D, Ødum N, Woetmann A.

Oncotarget. 2015 Jun 10;6(16):14374-84.

24.

IL-13 as a novel growth factor in CTCL.

Wasik MA.

Blood. 2015 Apr 30;125(18):2737-8. doi: 10.1182/blood-2015-02-626432. No abstract available.

25.

Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.

Lauenborg B, Christensen L, Ralfkiaer U, Kopp KL, Jønson L, Dabelsteen S, Bonefeld CM, Geisler C, Gjerdrum LM, Zhang Q, Wasik MA, Ralfkiaer E, Ødum N, Woetmann A.

Oncotarget. 2015 Jun 20;6(17):15235-49.

26.

Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy.

Singh N, Qayyum S, Wasik MA, Luger SM.

Am J Hematol. 2015 Oct;90(10):964-5. doi: 10.1002/ajh.23987. Epub 2015 Apr 29. No abstract available.

27.

MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.

Ralfkiaer U, Lindahl LM, Litman T, Gjerdrum LM, Ahler CB, Gniadecki R, Marstrand T, Fredholm S, Iversen L, Wasik MA, Bonefeld CM, Geisler C, Krejsgaard T, Glue C, Røpke MA, Woetmann A, Skov L, Grønbæk K, Odum N.

Anticancer Res. 2014 Dec;34(12):7207-17. Erratum in: Anticancer Res. 2015 Feb;35(2):1219. Lindal, Lise [corrected to Lindahl, Lise M].

PMID:
25503151
28.

STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides.

Fredholm S, Gjerdrum LM, Willerslev-Olsen A, Petersen DL, Nielsen IØ, Kauczok CS, Wobser M, Ralfkiaer U, Bonefeld CM, Wasik MA, Krejsgaard T, Geisler C, Ralfkiaer E, Gniadecki R, Woetmann A, Odum N.

Anticancer Res. 2014 Oct;34(10):5277-86.

PMID:
25275020
29.

Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

Krejsgaard T, Willerslev-Olsen A, Lindahl LM, Bonefeld CM, Koralov SB, Geisler C, Wasik MA, Gniadecki R, Kilian M, Iversen L, Woetmann A, Odum N.

Blood. 2014 Jul 31;124(5):761-70. doi: 10.1182/blood-2014-01-551184. Epub 2014 Jun 23.

30.

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL).

Petersen DL, Krejsgaard T, Berthelsen J, Fredholm S, Willerslev-Olsen A, Sibbesen NA, Bonefeld CM, Andersen MH, Francavilla C, Olsen JV, Hu T, Zhang M, Wasik MA, Geisler C, Woetmann A, Odum N.

Leukemia. 2014 Oct;28(10):2109-12. doi: 10.1038/leu.2014.192. Epub 2014 Jun 12. No abstract available.

31.

Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin.

Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, Burke GA, Wasik MA, Merkel O, Kenner L, Laurenti E, Dick JE, Turner SD.

Oncogene. 2015 Apr 2;34(14):1843-52. doi: 10.1038/onc.2014.112. Epub 2014 May 12.

PMID:
24814516
32.

Transcriptional repressor domain of MBD1 is intrinsically disordered and interacts with its binding partners in a selective manner.

Hameed UF, Lim J, Zhang Q, Wasik MA, Yang D, Swaminathan K.

Sci Rep. 2014 May 9;4:4896. doi: 10.1038/srep04896.

33.

IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).

Willerslev-Olsen A, Litvinov IV, Fredholm SM, Petersen DL, Sibbesen NA, Gniadecki R, Zhang Q, Bonefeld CM, Wasik MA, Geisler C, Zhou Y, Woetmann A, Sasseville D, Krejsgaard T, Odum N.

Cell Cycle. 2014;13(8):1306-12. doi: 10.4161/cc.28256. Epub 2014 Mar 3.

34.

Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

Zhang Q, Wang HY, Wei F, Liu X, Paterson JC, Roy D, Mihova D, Woetmann A, Ptasznik A, Odum N, Schuster SJ, Marafioti T, Riley JL, Wasik MA.

J Immunol. 2014 Mar 15;192(6):2913-9. doi: 10.4049/jimmunol.1302951. Epub 2014 Feb 12.

35.

The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes.

Zhang Q, Wei F, Wang HY, Liu X, Roy D, Xiong QB, Jiang S, Medvec A, Danet-Desnoyers G, Watt C, Tomczak E, Kalos M, Riley JL, Wasik MA.

Am J Pathol. 2013 Dec;183(6):1971-80.

36.

Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen.

Luskin MR, Roy DB, Wasik MA, Loren AW.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e55-8. doi: 10.1016/j.clml.2013.11.010. Epub 2013 Nov 22. No abstract available.

PMID:
24393621
37.

Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

Marzec M, Halasa K, Liu X, Wang HY, Cheng M, Baldwin D, Tobias JW, Schuster SJ, Woetmann A, Zhang Q, Turner SD, Ødum N, Wasik MA.

J Immunol. 2013 Dec 15;191(12):6200-7. doi: 10.4049/jimmunol.1300744. Epub 2013 Nov 11.

38.

Intravascular large B cell lymphoma presenting as a thyroid mass.

Stonecypher M, Yan Z, Wasik MA, LiVolsi V.

Endocr Pathol. 2014 Sep;25(3):359-60. doi: 10.1007/s12022-013-9266-7. No abstract available.

PMID:
24014041
39.

Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma.

Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Bonefeld CM, Wasik MA, Koralov SB, Geisler C, Kilian M, Iversen L, Woetmann A, Odum N.

Toxins (Basel). 2013 Aug 14;5(8):1402-21. doi: 10.3390/toxins5081402. Review.

40.

Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.

Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.

Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.

41.

Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma.

Krejsgaard T, Litvinov IV, Wang Y, Xia L, Willerslev-Olsen A, Koralov SB, Kopp KL, Bonefeld CM, Wasik MA, Geisler C, Woetmann A, Zhou Y, Sasseville D, Odum N.

Blood. 2013 Aug 8;122(6):943-50. doi: 10.1182/blood-2013-01-480889. Epub 2013 Jun 25.

42.

Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas.

Marstrand T, Ahler CB, Ralfkiaer U, Clemmensen A, Kopp KL, Sibbesen NA, Krejsgaard T, Litman T, Wasik MA, Bonefeld CM, Grønbæk K, Gjerdum LM, Gniadecki R, Ralfkiaer E, Geisler C, Woetmann A, Røpke MA, Glue C, Skov L, Odum N.

Leuk Lymphoma. 2014 Apr;55(4):957-8. doi: 10.3109/10428194.2013.815352. Epub 2013 Jul 29. No abstract available.

PMID:
23772646
43.

Targeting CD30 in malignant tissues: challenges in detection and clinical applications.

Wasik MA, Jimenez GS, Weisenburger DD.

Pathobiology. 2013;80(5):252-8. doi: 10.1159/000347192. Epub 2013 May 9. Review.

44.

STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.

Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jønson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C, Wasik MA, Ralfkiaer E, Ødum N, Woetmann A.

Cell Cycle. 2013 Jun 15;12(12):1939-47. doi: 10.4161/cc.24987. Epub 2013 May 15.

45.

ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.

Sun Y, Nowak KA, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, Liu N, Werner-Wasik M, Wasik MA, Dicker AP, Lu B.

Mol Cancer Ther. 2013 May;12(5):696-704. doi: 10.1158/1535-7163.MCT-12-0868. Epub 2013 Feb 26.

46.

Vascular endothelial growth factor receptor-3 expression in mycosis fungoides.

Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C, Krejsgaard T, Lauenborg B, Kopp KL, Geisler C, Bonefeld CM, Zhang Q, Wasik MA, Dabelsteen S, Woetmann A, Becker JC, Odum N.

Leuk Lymphoma. 2013 Apr;54(4):819-26. doi: 10.3109/10428194.2012.726720. Epub 2012 Sep 28.

PMID:
22946664
47.

Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.

Lee SC, Marzec M, Liu X, Wehrli S, Kantekure K, Ragunath PN, Nelson DS, Delikatny EJ, Glickson JD, Wasik MA.

NMR Biomed. 2013 Jan;26(1):106-14. doi: 10.1002/nbm.2825. Epub 2012 Jun 18.

48.

The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma.

Abraham RM, Zhang Q, Odum N, Wasik MA.

Cancer Biol Ther. 2011 Dec 15;12(12):1019-22. doi: 10.4161/cbt.12.12.18144. Epub 2011 Dec 15. Review.

49.

Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.

Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA.

PLoS One. 2011;6(9):e24849. doi: 10.1371/journal.pone.0024849. Epub 2011 Sep 16.

50.

Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.

Krejsgaard T, Odum N, Geisler C, Wasik MA, Woetmann A.

Leukemia. 2012 Mar;26(3):424-32. doi: 10.1038/leu.2011.237. Epub 2011 Sep 9. Review.

PMID:
21904385

Supplemental Content

Loading ...
Support Center